Generalized Myasthenia Gravis Market is Expected to Expand by 2032, Assesses DelveInsight | Key Companies - Alexion, Argenx, UCB, Horizon, Roche, Janssen Bristol Myers Squibb, Biogen Pfizer, Novartis, Sanofi, Takeda

DelveInsight's analysts estimate that the generalized myasthenia gravis market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and the anticipated launch of novel therapies during the forecast period (2023–2032). 

LAS VEGAS, Aug. 9, 2023 /PRNewswire/ -- DelveInsight's Generalized Myasthenia Gravis Market Insights report includes a comprehensive understanding of current treatment practices, generalized myasthenia gravis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Generalized Myasthenia Gravis Market Report

• As per DelveInsight analysis, the generalized myasthenia gravis market size was approximately USD 2.6 billion in 2021 and it is expected to grow positively at a significant CAGR during the study period (2019–2032).
• According to the assessment done by DelveInsight, the total number of diagnosed prevalent cases of generalized myasthenia gravis associated in the 7MM countries was approximately 116K in 2021. 
• Leading generalized myasthenia gravis companies such as UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others are developing novel generalized myasthenia gravis drugs that can be available in the generalized myasthenia gravis market in the coming years.
• Some key therapies for generalized myasthenia gravis treatment include Rozanolixizumab, Zilucoplan, Subcutaneous Efgartigimod, Uplizna (Inebilizumab), Enspryng (Satralizumab), Nipocalimab, Batoclimab, Tolebrutinib, Descartes-08, Mezagitamab (TAK-079), DAS-001, and others.

Discover which therapies are expected to grab the major generalized myasthenia gravis market share @ Generalized Myasthenia Gravis Market Report

Generalized Myasthenia Gravis Overview

Generalized myasthenia gravis is a chronic autoimmune disorder that affects the neuromuscular junction, leading to muscle weakness and fatigue. This condition occurs when the body's immune system mistakenly targets and attacks the acetylcholine receptors on the muscles, hindering communication between nerves and muscles. The exact cause of generalized myasthenia gravis remains unclear, but it is believed to involve a combination of genetic predisposition and environmental factors.

The hallmark symptom of generalized myasthenia gravis is muscle weakness, which typically worsens with repetitive use and improves with rest. It can affect various muscle groups, including those responsible for eye movements, facial expressions, swallowing, and limb movements. Common generalized myasthenia gravis symptoms include drooping eyelids, double vision, difficulty speaking, chewing, or swallowing, and weakness in the arms and legs. Diagnosing generalized myasthenia gravis can be challenging as its symptoms can mimic other neuromuscular disorders. A comprehensive evaluation by a neurologist is essential, which may include a detailed medical history, physical examination, and various specialized tests.

Generalized Myasthenia Gravis Epidemiology Segmentation

The generalized myasthenia gravis epidemiology section provides insights into the historical and current generalized myasthenia gravis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. 

The generalized myasthenia gravis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Generalized Myasthenia Gravis Diagnosed Prevalent Cases 
• Generalized Myasthenia Gravis Gender-Specific Cases 
• Autoantibodies-Specific Cases of Generalized Myasthenia Gravis 

Generalized Myasthenia Gravis Treatment Market 

The primary goal of treating generalized myasthenia gravis is to improve muscle strength, enhance physical function, and achieve remission whenever possible. The mainstay of treatment involves pharmacotherapy, with acetylcholinesterase inhibitors being used to increase the availability of acetylcholine at neuromuscular junctions, thereby improving muscle contraction. Additionally, immunosuppressive agents like corticosteroids, azathioprine, mycophenolate, or methotrexate may be prescribed to suppress the overactive immune response and reduce the production of autoantibodies that attack acetylcholine receptors. In recent years, biologic agents such as rituximab and eculizumab have shown promise in specific cases.

Thymectomy, the surgical removal of the thymus gland, is recommended for some patients, especially those under 55 years of age with thymic hyperplasia or thymoma, as it can lead to significant clinical improvements. Furthermore, supportive therapies like physical and occupational therapy are crucial components of the treatment plan. These therapies help maintain muscle strength, optimize daily functioning, and enhance the patient's overall quality of life.

The treatment for generalized myasthenia gravis is highly individualized, and the management plan is often adjusted based on the patient's response to different therapies and the severity of their symptoms. Regular follow-ups and close monitoring are essential to ensure optimal outcomes and to adapt the treatment approach as needed. With a comprehensive and personalized treatment regimen, many individuals with generalized myasthenia gravis can lead fulfilling lives and manage their condition effectively.

To know more about generalized myasthenia gravis treatment, visit @ Generalized Myasthenia Gravis Treatment Drugs 

Key Generalized Myasthenia Gravis Therapies and Companies

• Rozanolixizumab: UCB Biopharma
• Zilucoplan: UCB Biopharma
• Subcutaneous Efgartigimod: Argenx-Halozyme Therapeutics
• Uplizna (Inebilizumab): Horizon Therapeutics
• Enspryng (Satralizumab): Hoffmann-La Roche
• Nipocalimab: Janssen Research & Development, LLC
• Batoclimab: Immunovant Sciences GmbH
• Tolebrutinib: Sanofi
• Descartes-08: Cartesian Therapeutics
• Mezagitamab (TAK-079): Takeda
• DAS-001: DAS Therapeutics, Inc.

Learn more about the FDA-approved drugs for generalized myasthenia gravis @ Drugs for Generalized Myasthenia Gravis Treatment 

Generalized Myasthenia Gravis Market Dynamics

The generalized myasthenia gravis market is influenced by several key drivers that contribute to its growth and advancement. Firstly, the increasing prevalence of generalized myasthenia gravis cases, particularly among the aging population, has bolstered the demand for effective therapies. This, coupled with improved disease awareness and early diagnosis, has led to a larger patient pool seeking medical intervention.

Moreover, pharmaceutical companies' growing research and development efforts have resulted in the emergence of innovative treatment options for generalized myasthenia gravis. Biologics and targeted therapies, such as monoclonal antibodies, have shown promising outcomes, enhancing patients' quality of life and expanding the treatment landscape. Additionally, supportive initiatives by healthcare authorities and organizations, along with favorable reimbursement policies, have facilitated patient access to these novel treatments, further driving generalized myasthenia gravis market growth.

Despite the positive momentum, the generalized myasthenia gravis market also faces certain barriers. One significant challenge is the high cost associated with advanced therapies, making them inaccessible to some patients, particularly in regions with limited healthcare resources. Moreover, the complex nature of generalized myasthenia gravis and its varying manifestations make accurate diagnosis and disease management intricate, leading to potential delays in treatment initiation and inadequate disease control.

Furthermore, as with any chronic disorder, adherence to long-term treatment regimens can be a barrier, impacting treatment efficacy and patient outcomes. Addressing these challenges requires ongoing collaboration between healthcare providers, researchers, regulatory bodies, and pharmaceutical companies to develop cost-effective and patient-friendly treatment options and improve disease management strategies for individuals living with generalized myasthenia gravis.

Scope of the Generalized Myasthenia Gravis Market Report

• Therapeutic Assessment: Generalized Myasthenia Gravis current marketed and emerging therapies
• Generalized Myasthenia Gravis Market Dynamics: Conjoint Analysis of Emerging Generalized Myasthenia Gravis Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Generalized Myasthenia Gravis Market Access and Reimbursement

Discover more about generalized myasthenia gravis drugs in development @ Generalized Myasthenia Gravis Clinical Trials

Table of Contents

Related Reports

Generalized Myasthenia Gravis Pipeline

Generalized Myasthenia Gravis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key generalized myasthenia gravis companies, including Biocon, Cartesian Therapeutics, UCB, Momenta Pharmaceuticals, HanAll Biopharma, Roche, Alexion, Novartis, Takeda, BioMarin, among others.

Generalized Myasthenia Gravis Epidemiology

Generalized Myasthenia Gravis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted generalized myasthenia gravis epidemiology in the 7MM.

Myasthenia Gravis Market

Myasthenia Gravis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key myasthenia gravis companies, including Viela Bio, UCB Pharma, Momenta Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Hoffmann-La Roche, Alexion Pharmaceuticals, Catalyst Pharmaceuticals, Harbour BioMed, Novartis, Takeda, DAS Therapeutics, RemeGen, Cartesian Therapeutics, Nanjing IASO Biotherapeutics, Cabaletta Bio, CytoDyn, Ahead Therapeutics, Toleranzia, Rallybio, among others.

Myasthenia Gravis Pipeline

Myasthenia Gravis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including Viela Bio, UCB Pharma, Momenta Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Hoffmann-La Roche, Alexion Pharmaceuticals, Catalyst Pharmaceuticals, Harbour BioMed, Novartis, Takeda, DAS Therapeutics, RemeGen, Cartesian Therapeutics, Nanjing IASO Biotherapeutics, Cabaletta Bio, CytoDyn, Ahead Therapeutics, Toleranzia, Rallybio, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
info@delveinsight.com   
+1(919)321-6187
www.delveinsight.com    

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg